CYP19A1 and breast cancer: Although aromatase inhibitors are used clinically to treat post-menopausal women with estrogen receptor-positive breast cancer [18], there are some reports of patients in whom an aromatase inhibitor was effective against GCTs with repeated recurrences [15-17], as for patient 2.